Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Xenotransplantation: an update.

A J d'Apice1, D J Goodman, M J Pearse

  • 1Immunology Research Centre, St. Vincent's Hospital, Fitzroy, Victoria, Australia.

Trends in Cardiovascular Medicine
|February 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and effectiveness of a smartphone access program for promoting engagement in care among perinatal people with substance use disorders: a pilot study.

Frontiers in health services·2025
Same author

Ex vivo restimulation of human PBMC expands a CD3+CD4-CD8- γδ+ T cell population that can confound the evaluation of CD4 and CD8 T cell responses to vaccination.

Clinical & developmental immunology·2013
Same author

Overcoming hyperacute xenograft rejection with transgenic animals.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.

Vaccine·2004
Same author

Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2002
Same author

Effect of DNA concentration on transgenesis rates in mice and pigs.

Transgenic research·2002
Same journal

Artificial Intelligence in Echocardiography for Valvular Heart Disease.

Trends in cardiovascular medicine·2026
Same journal

Inflammation as a Fulcrum in Cardiovascular Disease: The Evolving Case for High-Sensitivity C-Reactive Protein.

Trends in cardiovascular medicine·2026
Same journal

Comment on "advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation".

Trends in cardiovascular medicine·2026
Same journal

Response to: Comment on "Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation" (TCM-D-26-00198).

Trends in cardiovascular medicine·2026
Same journal

High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure - a review.

Trends in cardiovascular medicine·2026
Same journal

The cost of false dichotomies in a dynamic disease.

Trends in cardiovascular medicine·2026
See all related articles

Cardiac allotransplantation survival has improved, but organ shortages mean many patients with heart failure still die waiting. Artificial hearts offer temporary support but a lower quality of life than transplants.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Biomedical Engineering

Background:

  • Cardiac allotransplantation has become a more viable treatment for end-stage cardiac failure over the last two decades, with significant reductions in mortality and morbidity.
  • The demand for cardiac transplants has outpaced the availability of donor organs, leading to a critical shortage.
  • Unlike patients with renal failure who can utilize dialysis, patients with cardiac failure face limited options while awaiting a transplant.

Purpose of the Study:

  • To review the advancements and current status of cardiac allotransplantation.
  • To highlight the disparity between the need for cardiac transplants and organ availability.
  • To discuss the role and limitations of artificial hearts as a bridge to transplantation.

Main Methods:

Related Experiment Videos

  • Review of recent literature on cardiac allotransplantation outcomes.
  • Analysis of organ donor statistics and patient waiting lists.
  • Comparison of quality of life between cardiac allotransplantation and artificial heart devices.

Main Results:

  • Significant improvements in survival and reduced complications following cardiac allotransplantation.
  • A persistent and growing gap between the number of patients needing heart transplants and the available donor organs.
  • Artificial hearts provide essential bridging therapy but are associated with a lower quality of life compared to successful allotransplantation.

Conclusions:

  • Cardiac allotransplantation is a successful treatment for end-stage heart failure, but organ scarcity remains a major challenge.
  • The development of artificial hearts offers a temporary solution but does not fully address the long-term quality of life concerns.
  • Addressing the organ donor shortage is crucial to improve outcomes for patients with terminal cardiac failure.